Quinta-Analytica s.r.o.
Verified
Prague, Czechia
Not recruiting
A study to compare how the body absorbs perampanel in healthy adult men and women during fasting conditions
Clinical Trials Concierge
Prefer not to search? Our Concierge searches the trials for you.
What is this trial about?
A plain-language summary of the goals, design and what participants do
This study is designed to compare how the body absorbs two different versions of the medication perampanel. This medicine is typically used to treat epilepsy, a condition that affects the brain and can cause seizures. The two versions being compared are the test product, known as Perampanel 2 mg film-coated tablets, and the reference product, known as Fycompa.
The purpose of the study is to evaluate the bioequivalence, which means checking if both medications work in the same way and are absorbed by the body at similar rates. Participants will take a single dose of either the test product or the reference product while in a fasting state, which means they will not have eaten for a certain period before taking the medication. The study uses a crossover design, meaning participants will receive both types of medication at different times during the study period.
The research process
The trial runs in 3 steps – from screening to follow-up. Each step says what happens and what the team monitors.
Who can join the trial?
10 criteria
- Participants must be healthy males or females who are not currently pregnant or breastfeeding.
- Participants must be between 18 and 55 years of age on the day they sign the consent form.
- Participants must be non-smokers or former smokers who have not smoked for at least 6 months before taking the study medication.
- Participants must have a Body Mass Index (BMI), which is a measure of body fat based on height and weight, between 18.5 and 30.0.
- Participants must be available for the entire duration of the study and provide written informed consent, which is a signed document agreeing to take part.
- Participants must be in good health, which is confirmed by reviewing medical history, a physical exam, vital signs (such as heart rate, body temperature, and blood pressure), and a 12-lead ECG, which is a test that records the electrical activity of the heart.
- All laboratory screening results, such as blood or urine tests, must fall within the normal range.
- Female participants who could become pregnant must agree to use highly effective contraception, which are methods like hormonal pills, implants, or devices used to prevent pregnancy, and must continue using them for at least 30 days after the study ends.
- Male participants must also use contraception or barrier methods, such as condoms, if their partner could become pregnant.
- Participants must be able to speak and understand Czech fluently.
Who cannot join the trial?
24 criteria
- You have any acute or chronic diseases, which are short-term or long-lasting health conditions, that could affect the study results or your safety while taking the study drug.
- You have received a tattoo, body piercing, or any cosmetic skin treatment involving piercing within 90 days before the screening, unless the study doctor decides it is not important for the study.
- Your urine drug test or alcohol breath test shows positive results for drug or alcohol use during screening or check-in.
- Your urine cotinine test is positive, which means there are traces of nicotine (the substance found in tobacco) in your system.
- You are a female who is pregnant, breastfeeding, or unable to provide a pregnancy test result.
- Your body temperature is 37.0 °C or higher during screening or check-in.
- Your blood pressure is not between 90-140 mmHg for the top number (systolic) and 60-90 mmHg for the bottom number (diastolic), or your heart rate is not between 50-100 beats per minute.
- You test positive for HBsAg (Hepatitis B), HCV (Hepatitis C), or HIV (a virus that affects the immune system).
- You have anaemia, which means your haemoglobin (the protein in red blood cells that carries oxygen) is below 120 g/L for women or 130 g/L for men.
- You have participated in another clinical study within the last 30 days.
- You have a history of significant hypersensitivity, which is a severe allergic reaction, to the study drug, its ingredients, or any other medications, such as angioedema (swelling deep under the skin).
- You have a history of liver diseases or have high levels of serum transaminases, which are enzymes (ALT or AST) that indicate liver irritation or damage.
- You have rare inherited conditions involving trouble processing certain sugars, such as galactose intolerance, lactase deficiency, or glucose-galactose malabsorption.
- You have a history of suicidal or homicidal behavior, tendencies toward such actions, or previous attempts.
- You received a COVID-19 vaccine less than 14 days before screening or plan to be vaccinated during the study.
- You have been hospitalized due to COVID-19.
- You test positive for the SARS-CoV-2 virus via a PCR or antigen test.
- You have a serious mental disease or are unable to cooperate with the medical team.
- You misuse drugs or alcohol (more than 40 grams of pure ethanol per day for men or 20 grams for women), use solvents, or cannot stop consuming foods with methylxanthine (like coffee, tea, chocolate, or energy drinks) for 48 hours before taking the drug.
- You have had a clinically significant illness or major surgery within 28 days before the first dose.
- You have taken any over-the-counter drugs (medicines bought without a prescription), vitamins, herbal treatments, or food supplements within 14 days before the first dose.
- You have taken any prescription medications within 28 days before the first dose, unless it is hormonal contraceptives or hormone replacement therapy that has remained at the same dose for 90 days.
- You have used organ-toxic drugs or medications known to change how the liver processes medicine within 90 days before the first dose.
- You have donated blood (500 mL or more), plasma, or platelets within a specific recent timeframe before the first dose.
Clinical Trials Concierge
Prefer not to search? Our Concierge searches the trials for you.
Tell us about your condition – we search every trial in Europe and connect you with the right site.
We usually reply within a few days
Verified sites
All sites with verified contact details – recruitment status may not be available; ask directly
Trial locations
Where you can join this trial
Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.
Not recruitingNot finding your country?
Not sure what to do next?
Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.
Investigated drugs
Perampanel
is a medication being tested in this study to see how well it is absorbed and used by the body.
Fycompa
is a medication used as a comparison to the test product to check if it performs in a similar way within the body.
What is already known about the treatment
Perampanel
This medication is taken by mouth in the form of a film-coated tablet. It is an established medicine used to treat certain types of seizures in people with epilepsy. It works by blocking a specific chemical messenger in the brain called glutamate, which helps to reduce the overactive electrical signals that cause seizures. This drug belongs to a group of medicines known as anti-epileptic drugs.
Perampanel
This medication is taken by mouth in the form of a film-coated tablet. It is an established medicine used to treat certain types of seizures in people with epilepsy. It works by blocking a specific chemical messenger in the brain called glutamate, which helps to reduce the overactive electrical signals that cause seizures. This drug belongs to a group of medicines known as anti-epileptic drugs.
Investigated diseases
The provided source data indicates that the study is a bioequivalence trial conducted in healthy human subjects rather than a study of a specific disease. Consequently, no disease is being studied.
Trial detailsLast updated 7 Oct 2026
Age18+ yearsPhasePhase ITrial ID2023-504132-18-00Protocol codeCFA-1031-2-23Estimated enrolment36 patientsSponsorLaboratorios Cinfa S.A.
sourced from the EU Clinical Trials Register and site verification
Want to learn more about this trial or check if you can participate?